Moderna Inc (MIL:1MRNA)
€ 38.165 -0.445 (-1.15%) Market Cap: 14.61 Bil Enterprise Value: 9.32 Bil PE Ratio: 0 PB Ratio: 1.30 GF Score: 44/100

Moderna Inc R&D Day Transcript

Sep 13, 2023 / 05:00PM GMT
Stephane Bancel
Moderna, Inc. - CEO & Director

Thank you for those joining us here, and thank you for those joining us online today. Before I start, let me just remind you that we'll be making forward-looking statements. And of course, investing in Moderna entails risk. Please look at these documents online, on the SEC website for your information. So 10-plus years ago, we started Moderna, believing that mRNA could be a very powerful molecule, an information molecule to make a new class of medicines.

And it was really exciting to us having spent years in pharma, having suffered from the small molecule failure rates, large molecule and the limitations. The notion that you can use an information molecule to make medicines was really, really exciting. And as you know, because many of you have seen these slides for now 10 years, what excited us is a few things. The first thing was the opportunity to have a very large product opportunity sets. The ability to go and do secreted proteins or combinations of secretive proteins. The ability to transmembrane proteins are very complex transmembrane

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot